MURA 3.65 Mural Oncology plc
| Range: | 2.88-6.25 | Vol Avg: | 96120 | Last Div: | 0 | Changes: | -0.04 |
| Beta: | 0 | Cap: | 0.06B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Nov 16 2023 | Empoloyees: | 107 | ||
| CUSIP: | CIK: | 0001971543 | ISIN: | IE000LK2BOB4 | Country: | IE | |
| CEO: | Ms. Caroline J. Loew Ph.D. | Website: | https://www.muraloncology.com | ||||
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow